UBE2C

Across TCGA pan-cancer cohorts, UBE2C Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated UBE2C data layer compared with 28 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher UBE2C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE2C expression acts as an unfavorable survival marker.

BLCA and STAD are the cancer types where UBE2C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.090	0.572	<.001	24	view →
STAD	OS	Median	All	0.257	0.688	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

UBE2C–BLCA (DFS)

Open the BLCA breakdown →